Genomic profiling of this patient suggests that AITL arose from a founder clone harboring DNMT3A and TET2 mutations; the addition of the IDH2 mutation was presumably associated with progression to AITL. This evidence concerns the gene TET2 and angioimmunoblastic T-cell lymphoma.